Pharma Stability: Insights, Guidelines, and Expertise
Navigating Retest Periods and Expiry Dates in Regulatory Submissions Updated September 2025 — A compliance-ready guide for CMC teams to correctly justify and document retest periods (drug substance) and expiry dates (drug product) in eCTD dossiers. When regulators review your dossier, they expect absolute clarity on one deceptively simple distinction: retest period vs. expiry date….
One of the most frequent errors is using the terms “shelf life” and “re-test period” interchangeably. While related, they serve different purposes:
Click to read the full article.
A re-test period is not an expiry date. Rather, it’s the interval after which a material must be re-evaluated through testing to ensure it still meets specification. Materials that pass re-testing can continue to be used.
Click to read the full article.
The re-test period is the duration during which a material, typically an API or intermediate, must be re-analyzed to ensure continued quality. Unlike a fixed expiry date, the re-test period allows use after retesting — provided the results meet specifications.
Click to read the full article.
APIs can exist in two primary forms before formulation:
Click to read the full article.
SOPs serve as the foundation for consistent and traceable retesting practices. They define who does what, when, and how — ensuring that materials are not used unless they meet specification through validated reanalysis. Regulatory bodies such as the USFDA and EMA expect that every retesting decision is traceable to documented procedures and stability data.
Click to read the full article.
The event occurred at a mid-sized pharmaceutical company exporting APIs to the US, EU, and Indian markets. The Quality Assurance (QA) team received an FDA Form 483 observation following a routine inspection, citing “labeling inconsistencies and incorrect use of expiry date on API batch containers.”
Click to read the full article.
The concept of re-test periods originates from ICH Q7 guidelines, which apply to APIs and pharmaceutical intermediates. It defines a re-test date as:
Click to read the full article.
The concept of re-test periods originates from ICH Q7 guidelines, which apply to APIs and pharmaceutical intermediates. It defines a re-test date as:
Click to read the full article.
Before initiating any stability protocol, it’s crucial to understand the nature and sensitivity of the intermediate. This step informs your study design, test parameters, and expected degradation risks.
Click to read the full article.